Pneumoccal polysacchride conjugate vaccine
US-9884113-B2 · Feb 6, 2018 · US
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11090375B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11090375-B2 |
| Application number | US-202016899738-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 12, 2020 |
| Priority date | Jan 21, 2014 |
| Publication date | Aug 17, 2021 |
| Grant date | Aug 17, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A multivalent immunogenic composition comprising polysaccharide-protein conjugates and a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, wherein the polysaccharide-protein conjugates consist of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, wherein the carrier protein is CRM 197 , and wherein said serotype 15B capsular polysaccharide-protein conjugate comprises: (a) at least 0.1 mM acetate per mM serotype 15B capsular polysaccharide, and (b) less than 50% of free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide. 2. A multivalent immunogenic composition according to claim 1 , further comprising at least one adjuvant. 3. A multivalent immunogenic composition according to claim 2 , wherein said at least one adjuvant is selected from the group consisting of a CpG oligonucleotide, aluminum hydroxide, aluminum phosphate, and aluminum sulfate, or a combination thereof. 4. A multivalent immunogenic composition according to claim 1 , further comprising a pharmaceutically acceptable excipient, carrier or diluent.
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Inorganic adjuvants · CPC title
Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title
- A61K39/092Primary
Streptococcus · CPC title
Multivalent vaccine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11090375B2 cover?
- The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccin…
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification A61K39/092. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).